In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin
The ongoing opioid crisis has affected countless lives, leaving individuals and families grappling with addiction and its devastating consequences. Amid this turmoil, researchers funded by the National Institutes of Health (NIH) have been diligently working on a novel solution that could change the
Resistant hypertension affects more than half of patients suffering from high blood pressure, presenting a significant challenge for healthcare providers. This condition often remains uncontrolled by multiple medications, typically linked to elevated levels of aldosterone, a hormone regulating
The recent halt of life-saving drug trials due to an unanticipated funding freeze by the U.S. government has created significant uncertainty and disruption in the fight against malaria, a disease that remains a major global health threat. This decision, stemming from an initiative by the Trump
The dawn of holography technology marks a revolutionary period in healthcare, enhancing diagnostic capabilities, surgical planning, and medical education. With predictions of the global medical holography market reaching $7.11 billion by 2029, the healthcare sector stands on the brink of profound
Ivan Kairatov is a Biopharma expert, with deep knowledge in tech and innovation in the industry and experience in research and development. Today, we will discuss the intricacies of protein kinase research, the role of AI in predicting interactions, and the development of KinasePred. Can you
